Synthesis, biological evaluation, and docking studies of novel heterocyclic diaryl compounds as selective COX-2 inhibitors

被引:95
作者
Eren, Goekcen [1 ]
Unlu, Serdar [1 ]
Nunez, Maria-Teresa [2 ,3 ]
Labeaga, Luis [2 ,3 ]
Ledo, Francisco [2 ,3 ]
Entrena, Antonio [4 ]
Banoglu, Erden [1 ]
Costantino, Gabriele [5 ]
Sahin, M. Fethi [1 ]
机构
[1] Gazi Univ, Fac Pharm, Dept Pharmaceut Chem, TR-06330 Ankara, Turkey
[2] Faes Farma SA, R&D, Leioa 48940, Spain
[3] Faes Farma SA, Innovat Dept, Leioa 48940, Spain
[4] Fac Farm, Granada 18071, Spain
[5] Univ Parma, Dipartimento Farmaceut, I-43100 Parma, Italy
关键词
Diaryl heterocyclic; COX inhibition; Benzoxazole; Furanone; Oxazolone; Pyrazole; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CYCLOOXYGENASE-2; INHIBITORS; SYNTHASE CYCLOOXYGENASE; AGENTS; DERIVATIVES; DISCOVERY; METABOLITES; ROFECOXIB; COXIBS;
D O I
10.1016/j.bmc.2010.07.009
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Three novel series of diaryl heterocyclic derivatives bearing the 2-oxo-5H-furan, 2-oxo-3H-1,3-oxazole, and 1H-pyrazole moieties as the central heterocyclic ring were synthesized and their in vitro inhibitory activities on COX-1 and COX-2 isoforms were evaluated using a purified enzyme assay. The 2-oxo-5H-furan derivative 6b was identified as potent COX inhibitor with selectivity toward COX-1 (COX-1 IC(50) = 0.061 mu M and COX-2 IC(50) = 0.325 mu M; selectivity index (SI) = 0.19). Among the 1H-pyrazole derivatives, 11b was found to be a potent COX-2 inhibitor, about 38 times more potent than Rofecoxib (COX-2 IC(50) = 0.011 mu M and 0.398 mu M, respectively), but showed no selectivity for COX-2 isoform. Compound 11c demonstrated strong and selective COX-2 inhibitory activity (COX-1 IC(50) = 1 mu M, COX-2 IC(50) = 0.011 mu M; SI = similar to 92). Molecular docking studies of compounds 6b and 11b-d into the binding sites of COX-1 and COX-2 allowed to shed light on the binding mode of these novel COX inhibitors. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6367 / 6376
页数:10
相关论文
共 47 条
[31]   Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx™) [J].
Nicoll-Griffith, DA ;
Yergey, JA ;
Trimble, LA ;
Silva, JM ;
Li, C ;
Chauret, N ;
Gauthier, JY ;
Grimm, E ;
Léger, S ;
Roy, P ;
Thérien, M ;
Wang, ZY ;
Prasit, P ;
Zamboni, R ;
Young, RN ;
Brideau, C ;
Chan, CC ;
Mancini, J ;
Riendeau, D .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (23) :2683-2686
[32]  
ONEILL GP, 1994, MOL PHARMACOL, V45, P245
[33]   PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-1 AND SYNTHASE-2 [J].
OTTO, JC ;
SMITH, WL .
JOURNAL OF LIPID MEDIATORS AND CELL SIGNALLING, 1995, 12 (2-3) :139-156
[34]  
OZCELIK B, 2003, ARCH PHARM PHARM MED, V336, P406
[35]   RESTART PROCEDURES FOR CONJUGATE GRADIENT METHOD [J].
POWELL, MJD .
MATHEMATICAL PROGRAMMING, 1977, 12 (02) :241-254
[36]   The discovery of rofecoxib, [MK 966, Vioxx®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor [J].
Prasit, P ;
Wang, Z ;
Brideau, C ;
Chan, CC ;
Charleson, S ;
Cromlish, W ;
Ethier, D ;
Evans, JF ;
Ford-Hutchinson, AW ;
Gauthier, JY ;
Gordon, R ;
Guay, J ;
Gresser, M ;
Kargman, S ;
Kennedy, B ;
Leblanc, Y ;
Léger, S ;
Mancini, J ;
O'Neill, GP ;
Ouellet, M ;
Percival, MD ;
Perrier, H ;
Riendeau, D ;
Rodger, I ;
Tagari, P ;
Thérien, M ;
Vickers, P ;
Wong, E ;
Xu, LJ ;
Young, RN ;
Zamboni, R ;
Boyce, S ;
Rupniak, N ;
Forrest, N ;
Visco, D ;
Patrick, D .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (13) :1773-1778
[37]  
RENARD P, 1980, EUR J MED CHEM, V15, P453
[38]  
Riendeau D, 2001, J PHARMACOL EXP THER, V296, P558
[39]   Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1 [J].
Rimon, Gilad ;
Sidhu, Ranjinder S. ;
Lauver, D. Adam ;
Lee, Jullia Y. ;
Sharma, Narayan P. ;
Yuan, Chong ;
Frieler, Ryan A. ;
Trievel, Raymond C. ;
Lucchesi, Benedict R. ;
Smith, William L. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (01) :28-33
[40]  
ROGIER DJ, 1977, J MED CHEM, V40, P1347